UroGen Pharma Ltd. (URGN)

UroGen Pharma's stock price experienced significant events in the past six months. In May 2025, the stock price dropped approximately 47% after the FDA's ODAC voted against the risk/benefit profile of UGN-102. In July 2025, UroGen Pharma unveiled findings from a five-year extension of its Phase 2b OPTIMA II study for ZUSDURI. In September 2025, analysts projected that UroGen Pharma could reach breakeven around 2027. In November 2025, UroGen reported its Third Quarter 2025 financial results, highlighting progress in the launch of ZUSDURI and revenue growth for JELMYTO. In December 2025, UroGen Pharma announced inducement grants of restricted stock units to new employees. In January 2026, a permanent J Code for ZUSDURI™ became effective.

UroGen Pharma Ltd. has seasonality in its stock returns, but the available search results do not provide specific details or patterns regarding the demand seasonality for UroGen Pharma's products and services.

UroGen Pharma Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative solutions for urological and uro-oncological diseases, particularly urothelial and specialty cancers. The company's core business revolves around its proprietary RTGel™ reverse-thermal hydrogel technology, designed to improve the therapeutic profiles of existing drugs by enabling sustained drug delivery to the urinary tract. UroGen's major products and pipeline candidates include Jelmyto, an FDA-approved non-surgical treatment for low-grade upper tract urothelial cancer, ZUSDURI, approved for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, UGN-103, targeting recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, UGN-104, designed for low-grade upper tract urothelial cancer, and UGN-301 series, for the treatment of high-grade non-muscle invasive bladder cancer.

UroGen Pharma Ltd. is headquartered in Princeton, New Jersey, United States, with research and development operations located in Israel. The company focuses on delivering its therapies to key urology and oncology centers across the United States and aims to expand the availability of its products to international markets through partnerships and collaborations.

UroGen Pharma's brand reputation has been characterized by both significant advancements and challenges. The company has received strong analyst support, with seven buy ratings and one hold rating. The successful launch and market acceptance of Jelmyto and ZUSDURI, along with promising clinical trial results for pipeline products, have positively contributed to its reputation. However, the FDA's ODAC vote against the risk/benefit profile of UGN-102 in May 2025 negatively impacted UroGen Pharma's reputation and stock price.

UroGen Pharma Ltd. has 263 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 46,414,152 shares. Major institutional shareholders include RTW Investments, LP, Paradigm Biocapital Advisors LP, Toronto Dominion Bank, BlackRock, Inc., Morgan Stanley, Jefferies Financial Group Inc., Silverarc Capital Management, Llc, Millennium Management Llc, Acorn Capital Advisors, Llc and SG Americas Securities, LLC. Other notable institutional holders include Cowen Inc., Soleus Capital Master Fund, L.P., and Menora Mivtachim Holdings Ltd.